Interim analysis of a phase 2 trial in 568 healthy adults: the Vero cell yellow fever vaccine vYF was non-inferior to YF-VAX for day-29 seroconversion (99.7% vs 99.4%, per-protocol 485), with similar safety.
RCTn = 568
Feroldi et al. Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial